{"disease":{"id":"colorectal-tumors","name":"colorectal tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05693519","title":"GastroIntestinal Cancer in Children and Adolescents","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Paul G. Kemps, MD","has_results":false},{"nct_id":"NCT05379985","title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":754,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT06040541","title":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":604,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04449874","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":498,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT04482309","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":477,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02178722","title":"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02009449","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT03947385","title":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":336,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT01174121","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":332,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03377361","title":"An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT03935893","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Udai Kammula","has_results":false},{"nct_id":"NCT03752398","title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT02646748","title":"Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT03314935","title":"A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06973161","title":"ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03329950","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT04256707","title":"Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Karyopharm Therapeutics Inc","has_results":false},{"nct_id":"NCT07435038","title":"Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Betta Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06614751","title":"A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Danatlas Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT03428958","title":"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"NuCana plc","has_results":true},{"nct_id":"NCT07202364","title":"A Study of YL202 in Patients With Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"MediLink Therapeutics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT03470883","title":"Predictive Factors for Failure or Success of Endoscopic Treatment of Superficial Colorectal Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT05484687","title":"Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Affiliated Hospital of Nantong University","has_results":false},{"nct_id":"NCT00819169","title":"QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":89,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT03597581","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Inspirna, Inc.","has_results":false},{"nct_id":"NCT04344795","title":"Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Tempest Therapeutics","has_results":false},{"nct_id":"NCT04579757","title":"Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":87,"lead_sponsor_name":"Hutchmed","has_results":true},{"nct_id":"NCT06910657","title":"IDOV-Immune for Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"ViroMissile, Inc.","has_results":false},{"nct_id":"NCT05358249","title":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03833700","title":"A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT02746224","title":"Reconstruction Techniques and Vascular Approach After Laparoscopic Left Hemicolectomy and Rectum Low Anterior Resection","phase":"NA","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","has_results":false},{"nct_id":"NCT04403022","title":"da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Intuitive Surgical","has_results":false},{"nct_id":"NCT06549907","title":"A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT07260058","title":"Immune Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.","has_results":false},{"nct_id":"NCT01291420","title":"Dendritic Cell Vaccination for Patients with Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT05877599","title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03319459","title":"FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT05731947","title":"Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT04045496","title":"A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Jacobio Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03953235","title":"A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Gritstone bio, Inc.","has_results":false},{"nct_id":"NCT00378482","title":"A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05411133","title":"Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Arbele Pty Ltd","has_results":false},{"nct_id":"NCT04714983","title":"DNX-2440 for Resectable Colorectal Liver Metastasis","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":30,"lead_sponsor_name":"DNAtrix, Inc.","has_results":false},{"nct_id":"NCT03050814","title":"Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04440943","title":"A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Celldex Therapeutics","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}